Ligelizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ligelizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target IGHE
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
Formula C6534H10000N1716O2038S44
Molar mass 146.6 kDa

Ligelizumab (INN) is a humanized monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria.[1] It binds to IGHE an acts as an immunomodulator.[2]

This drug was developed by Novartis Pharma AG.

Adverse drug effects[edit]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ligelizumab, American Medical Association.
  2. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).